1. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (September 2021) Authors: Macaluso, F.S.; Cappello, M.; Crispino, F.; Grova, M.; Privitera, A.C.; Piccillo, G.; Magnano, A.; Ferracane, C.; Belluardo, N.; Giangreco, E.; Fries, W.; Viola, A.; Di Mitri, R.; Mocciaro, F.; Camilleri, S.; Garufi, S.; Renna, S.; Casà, A.; Maida, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021) Authors: Macaluso, F.S.; Cappello, M.; Busacca, A.; Fries, W.; Viola, A.; Costantino, G.; Magnano, A.; Vinci, E.; Ferracane, C.; Privitera, A.C.; Piccillo, G.; Belluardo, N.; Giangreco, E.; Romano, C.; Citrano, M.; Graziano, F.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Scrivo, B. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020) Authors: Macaluso, F.S.; Ventimiglia, M.; Fries, W.; Viola, A.; Cappello, M.; Scrivo, B.; Magnano, A.; Pluchino, D.; Camilleri, S.; Garufi, S.; Di Mitri, R.; Mocciaro, F.; Magrì, G.; Ferracane, C.; Citrano, M.; Graziano, F.; Bertolami, C.; Renna, S.; Orlando, R.; Rizzuto, G. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OC.06.2: The Sicilian Network of Biological Therapy in Inflammatory Bowel Disease: Preliminary Data from a Prospective Study on Efficacy and Safety. (15th March 2017) Authors: Orlando, A.; Fries, W.; Privitera, A.; Cappello, M.; Siringo, S.; Inserra, G.; Magnano, A.; Di Mitri, R.; Belluardo, N.; Scarpulla, G.; Magrì, G.; Trovatello, A.; Carroccio, A.; Genova, S.; Calandruccio, G.; Vassallo, R.; Romano, C.; Magazzù, G.; Citrano, M.; Accomando, S. Journal: Digestive and liver disease Issue: Volume 49(2017)Supplement 2 Page Start: e91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2. (1st October 2020) Authors: Macaluso, F.S.; Fries, W.; Viola, A.; Centritto, A.; Cappello, M.; Giuffrida, E.; Privitera, A.C.; Piccillo, G.; Magnano, A.; Vinci, E.; Vassallo, R.; Trovatello, A.; Belluardo, N.; Giangreco, E.; Camilleri, S.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Renna, S.; Orlando, R. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OC.12.3 SPOSIB SB2 – A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2 (FLIXABI®): INTERIM ANALYSIS. (25th March 2019) Authors: Macaluso, F.S.; Cappello, M.; Giuffrida, E.; Fries, W.; Centritto, A.; Privitera, A.C.; Inserra, G.; Vassallo, R.; Magnano, A.; Vinci, E.; Garufi, S.; Ventimiglia, M.; Renna, S.; Orlando, R.; Rizzuto, G.; Cottone, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 2 Page Start: e110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P.02.4 EFFECTIVENESS OF VEDOLIZUMAB ON INTESTINAL AND ARTICULAR OUTCOMES: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). Issue 2 (15th March 2018) Authors: Macaluso, F.S.; Orlando, R.; Fries, W.; Scolaro, M.; Magnano, A.; Pluchino, D.; Cappello, M.; Morreale, G.C.; Siringo, S.; Privitera, A.C.; Ferracane, C.; Belluardo, N.; Alberghina, N.; Ventimiglia, M.; Rizzuto, G.; Renna, S.; Cottone, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 50:Issue 2(2018)Supplement Page Start: e133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (September 2021) Authors: Macaluso, F.S.; Giuliano, A.; Fries, W.; Viola, A.; Abbruzzese, A.; Cappello, M.; Giuffrida, E.; Carrozza, L.; Privitera, A.C.; Magnano, A.; Ferracane, C.; Scalisi, G.; Minissale, M.G.; Giangreco, E.; Garufi, S.; Bertolami, C.; Cucinotta, U.; Graziano, F.; Renna, S.; Rizzuto, G. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗